Open
Do other lipid agents cause more adverse events & safety versus placebo?
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.00 (range 0.00–0.55)
- Trials for
- 0
- Trials against
- 4
- Inconclusive
- 0
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 118
- With posted results
- 20
- Published papers
- 10
Of 4 decided analyses: 3 favor other lipid agents, 1 find no difference, 0 favor the comparator.
Papers
- Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.Trial report · 2016
- Pharmacological interventions for asymptomatic carotid stenosis.Meta-analysis / systematic review · 2023
- Fibrates for primary prevention of cardiovascular disease events.Meta-analysis / systematic review · 2016
- Ezetimibe-Statin Combination Therapy.Meta-analysis / systematic review · 2016
- Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.Meta-analysis / systematic review · 2012
- Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey).Trial report · 2023
Trials
- A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)NCT00202878 · 1 posted result
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye StudyNCT00542178 · 3 posted results
- A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed DyslipidemiaNCT01012219 · 1 posted result
- Effects of High-dose StAtin Versus Low-dose Statin Plus Ezetimibe on Statin-Associated Muscle Symptoms & on Reaching Target LDL-C Levels Among Elderly Patients With Atherosclerotic Cardiovascular DiseaseNCT04826354
- Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients: a Randomized Crossover TrialNCT06381947
- ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cARTNCT01683656
- ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)NCT00397657
- Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)NCT06649240